These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8615129)

  • 21. Neuronal degeneration in human diseases and animal models.
    Price DL; Martin LJ; Clatterbuck RE; Koliatsos VE; Sisodia SS; Walker LC; Cork LC
    J Neurobiol; 1992 Nov; 23(9):1277-94. PubMed ID: 1469388
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experimental models of Parkinson's disease].
    Féger J; Pessigliore M; François C; Tremblay L; Hirsch E
    Ann Pharm Fr; 2002 Jan; 60(1):3-21. PubMed ID: 11976545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
    Brundin P; Angela Cenci M; Wieloch T
    Exp Neurol; 2006 Sep; 201(1):1-6. PubMed ID: 16806183
    [No Abstract]   [Full Text] [Related]  

  • 24. One-hit neuronal death.
    Heintz N
    Nature; 2000 Jul; 406(6792):137, 139. PubMed ID: 10910338
    [No Abstract]   [Full Text] [Related]  

  • 25. Dopaminergic graft-induced long-term recovery of complex sensorimotor behaviors in a rat model of Parkinson's disease.
    Nikkhah G; Rosenthal C; Falkenstein G; Samii M
    Zentralbl Neurochir; 1998; 59(2):97-103. PubMed ID: 9674098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
    Kazantsev AG; Kolchinsky AM
    Arch Neurol; 2008 Dec; 65(12):1577-81. PubMed ID: 19064744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine and adult neurogenesis.
    Borta A; Höglinger GU
    J Neurochem; 2007 Feb; 100(3):587-95. PubMed ID: 17101030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.
    Ferrari CC; Pott Godoy MC; Tarelli R; Chertoff M; Depino AM; Pitossi FJ
    Neurobiol Dis; 2006 Oct; 24(1):183-93. PubMed ID: 16901708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of monoamine toxicity in Parkinson's disease: hypothetical cell death model.
    Jimenez del Rio M; Velez-Pardo C
    Med Hypotheses; 2000 Feb; 54(2):269-74. PubMed ID: 10790763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcium, neuronal death and neurological disease].
    Jiménez-Jiménez FJ; García-Ruiz PJ; de Bustos F
    Rev Neurol; 1996 Oct; 24(134):1199-209. PubMed ID: 8983715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental models of Parkinson's disease: insights from many models.
    Tolwani RJ; Jakowec MW; Petzinger GM; Green S; Waggie K
    Lab Anim Sci; 1999 Aug; 49(4):363-71. PubMed ID: 10480640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone secretion in neurological disorders.
    Martinez-Campos A; Giovannini P; Cocchi D; Zanardi P; Parati EA; Caraceni T; Müller EE
    Adv Biochem Psychopharmacol; 1981; 28():521-40. PubMed ID: 6452036
    [No Abstract]   [Full Text] [Related]  

  • 37. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A; Rey P; Guerra MJ; Mendez-Alvarez E; Soto-Otero R; Labandeira-Garcia JL
    Neuropharmacology; 2006 Jul; 51(1):112-20. PubMed ID: 16678218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasticity of the nigropallidal pathway in Parkinson's disease.
    Whone AL; Moore RY; Piccini PP; Brooks DJ
    Ann Neurol; 2003 Feb; 53(2):206-13. PubMed ID: 12557287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter.
    Hartmann A; Hunot S; Hirsch EC
    Exp Neurol; 2003 Dec; 184(2):561-4. PubMed ID: 14769349
    [No Abstract]   [Full Text] [Related]  

  • 40. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine.
    Rodriguez-Blanco J; Martín V; Herrera F; García-Santos G; Antolín I; Rodriguez C
    J Neurochem; 2008 Oct; 107(1):127-40. PubMed ID: 18665912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.